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ABSTRACT 
Doxorubicin hydrochloride is one of the most commonly used cytotoxic anthracycline antibiotics used in cancer chemotherapy and has been shown to have 
activity against a wide variety of neoplasms. Conventional compositions of doxorubicin hydrochloride are available as freeze-dried product (or) as a solution 
of doxorubicin hydrochloride in  water. Both these  products have  been associated  with a number of toxicities  when administered intravenously.
  Several 
approaches  have  taken  in  an  effort  to increase  the  circulation  time  of  liposomes  by  coating  the  liposomal  surface  with  a  hydrophilic  polymer  such  as 
polyethylene glycol, but have new toxic effects appeared like skin toxicity generally known as “Hand-Foot Syndrome”
. In the present study Doxorubicin 
Liposomes were formulated by “Double emulsion method to form Multivescicular liposomes”. The influence of various formulation and process parameters 
using different ratios of inner aqueous phase: oil phase: outer aqueous phase, homogenization speed, homogenization time on encapsulation efficiency, % free 
drug, particle size, zeta potential, surface morphology and release were investigated. Less than 10 % free drug was achieved with double emulsion method. 
The Scanning Electron Microscopy image showed the spherical shape having 33 ± 5 µm particle sizes. The in-vitro drug release for optimized formulation was 
found to be controlled release of drug over a period of 7 days. 
Key words: Liposomes, Doxorubicin HCl, lipids, double emulsion method. 
 
INTRODUCTION 
Doxorubicin  hydrochloride  is  one  of  the  most  commonly 
used  cytotoxic  anthracycline  antibiotics  used  in  cancer 
chemotherapy and has been shown to have activity against a 
wide variety of neoplasms. The tumour must be exposed for a 
sufficient length of time so that all or most of the cancer cells 
have  attempted  to  synthesize  DNA  in  the  presence  of 
Doxorubicin
1.  Conventional  compositions  of  doxorubicin 
hydrochloride are available as freeze-dried product (or) as a 
solution of doxorubicin hydrochloride in water. Both these 
products  have  been  associated  with  a  number  of  toxicities 
when  administered  intravenously.  Severe  myelosupression, 
nausea,  vomiting,  alopecia,  mucosistis  &  cardio  toxicity, 
limits  the  use  of  Doxorubicin  HCl.  It  also  causes 
extravasations  &  necrosis  at  the  site  of  injection.  Several 
approaches have taken in an effort to increase the circulation 
time  of liposomes  by coating the liposomal surface  with a 
hydrophilic  polymer  such  as  polyethylene  glycol  (PEG)  to 
prevent adsorption  of  various  blood plasma proteins to the 
liposome surface. The marketed preparation of Doxorubicin 
Hydrochloride  in  the  form  of  Pegylated  Liposomes  is 
available  on  the  name  of  DOXIL  manufactured  by  Ben 
Venue Laboratories, Inc
2.These liposomes appeared to reduce 
some  of  the  toxic  effects  caused  by  the  release  of  their 
contents,  but  have  new  toxic  effects  appeared  like  skin 
toxicity  generally  known  as  “Hand-Foot  Syndrome”
  3.  To 
overcome these problems, an alternative approach is needed. In 
the present study Doxorubicin Liposomes are Formulated by 
“Double  emulsion  method  to  form  Multivescicular 
liposomes” to check effect of drug loading and particle size. 
The  present  investigation  meets  this  need  by  providing 
compositions  of  multivesicular  liposomes  useful  as  a 
sustained  release  drug  delivery  system  by  intramuscular 
(I.M.)  administration.  Multivesicular  liposomes  contain 
multiple  non  -  concentric  aqueous  chambers  per  particle 
within  each  liposome  particle,  resembling  “foam”  like 
matrix
4. 
 
MATERIALS AND METHODS 
Materials 
Doxorubicin  hydrochloride  was  purchased  from  Sterling 
Biotech,  China.  Di-Olelyl-Phosphatidyl  Choline,  Di-
Palmitoyl-Phosphatidyl  Glycerol,  Triolein  and  Cholesterol 
were  purchased  from  Lipoid  Pvt.  Ltd,  Mumbai.  The 
laboratory grade chemicals used for the work are Lysine HCl, 
Sucrose,  Glucose,  Sodium  chloride,  Chloroform,  Sodium 
hydroxide,  Triton,  Acetonitrile  are  purchased  from  Merck 
Chemicals Pvt., Ltd. Mumbai. 
 
Compatibility studies 
IR spectroscopy can be used to investigate and predict any 
physicochemical  interactions  between  different  components 
in  a  formulation  and  therefore  it  can  be  applied  to  the 
selection  of suitable chemically compatible excipients.  The 
aim  of  the  present  study  was  to  test,  whether  there  is  any 
interaction between the carriers and drug; The following IR 
spectroscopy was recorded. 
Preparation of Doxorubicin HCl liposomes  
Doxorubicin  HCl  Liposomes  were  prepared  by  double 
emulsion solvent evaporation  method.  Inner aqueous  phase 
was  prepared by dissolving Doxorubicin  HCl in water and 
nitrogen  was  purged  for  5  min  after  it  got  completely 
dissolved. Outer aqueous phase was prepared by dissolving 
glucose (5%) and lysine (100 mM) in W.F I and purged with 
nitrogen  for  20  min.  Lipid  solution  was  prepared  by 
dissolving  weighed  quantities  of  lipids,  Di-Olelyl-
Phosphatidyl Choline (1.425 gm), Di-Palmitoyl-Phosphatidyl 
Glycerol  (0.250  gm),  Triolein  (0.300  gm)  and  Cholesterol 
(1.025  gm)  in  chloroform  and  dissolved  the  lipids  by 
sonication for 5 min. Primary Emulsion (W1/O) was prepared 
by adding drop by drop Inner aqueous phase into the lipid 
solution  with  20  ml  syringe  by  High  shear  homogenizer.  
Secondary Emulsion (W1/O/W2) was prepared by pouring the 
primary emulsion slowly in to the glass beaker containing the 
Outer  aqueous  phase  by  High  shear  homogenizer.  The 
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bottom flask (RBF) containing aqueous solution 2 and rotated 
using Rota Vopour, to remove chloroform completely. After 
complete removal of chloroform, the solution present in RBF 
was transferred in to the centrifuge tubes, centrifugation was 
carried out for 20 min at 2000 rpm, supernatant was collected 
and sample was given for analysis of free drug. 100 ml of 
0.9% NaCl was added to collected wet liposomes to remove 
the free drug and again centrifuged for 10 min at 2000 rpm. 
Wet liposomes were collected after removal of supernatant, 
added  5  ml  of  0.9%  NaCl  and  re-dispersed  the  wet 
microspheres  by  vortexing  for  5  mins.  It  formed  the  red 
suspension  of  Doxorubicin  liposomes  and  make-up  with 
0.9% NaCl if required 
4, 5, 6. 
 
Characterization of Liposomes 
  Percent free drug  
Measure the absorbance of solution at 590nm using Glucose-
Lysine solution as blank. 
Transferred 0.1ml of sample to a 20 ml stoppered test tube, 
added  8ml  of  Glucose-Lysine  solution  to  it,  mix  well, 
measure  the  absorbance  at  590nm  using  calibrated  UV 
spectrophotometer. Transferred the solution from the cell to 
test  tube  (A1).To  the  above  test  tube  containing  solution, 
added 1ml sodium hydroxide solution, mix well and measure 
the absorbance at 590 nm using UV transfer the solution from 
the cell to test tube (A2).To the above test tube containing 
solution, added 1ml of Triton solution, mix well and measure 
the absorbance at 590 nm using calibrated UV (A3)
 7. 
Percent Free Doxorubicin Hcl = [(A2×1.125) –A1/A3×1.25] × 
100. 
 
Doxorubicin HCl Assay  
A  standard  and  sample  solution  was  prepared,  injected 
separately  20  µl  of  the  standard  and  sample  solution  in 
chromatographic condition and recorded the chromatogram. 
Calculate the content of drug per ml in liposomal injection as 
follows 
7. 
Assay= A/B×W/200×5/50×C/100×100-D/100×50/5×100/5 
Where, A = Area corresponding to Doxorubicin Hcl in 
sample. B = Area corresponding to Doxorubicin Hcl in 
working standard. C = % purity of Doxorubicin Hcl in 
working standard. D = % water content of working standard. 
W = Weight of working standard in mg. 
 
Particle size analysis and Zeta potential 
The  mean  diameter  and  surface  charge  of  liposomes  was 
determined by laser diffractometer (Mastersizer X, Malvern 
Instrument, UK). Liposomes were diluted from 1 to 10 fold 
prior to determination of particle size and Zeta potential 
8. 
 
Scanning Electron Microscopy (SEM) 
The  Morphology  and  surface  appearance  Liposomes  were 
examined by using SEM (Using Hitachi-S-3700N). Scanning 
electron  microscopy  was  carried  out  to  study  the 
morphological characteristics of Doxorubicin Hydrochloride 
Liposomes. The samples for the SEM analysis were prepared 
by placing the Liposomal solution on one side of adhesive 
stub.  Then  the  dried  liposomes  were  coated  with  gold 
(100A°) before  microscopy. Finally the  morphology  of the 
Liposomes  was  observed  with  the  scanning  electron 
microscopy
8. 
 
In vitro Release studies  
The in vitro release of drug from the liposomal formulation 
was  carried  out  by  using  dialysis  membrane  employing  in 
two sides open ended cylinder.4 ml of liposomal suspension 
containing known amount of drug was placed in a dialysis 
membrane previously soaked overnight. The two sides open 
cylinder was placed in 200 ml of PBS (pH 7.4), maintained at 
37
o C and stirred with the help of a magnetic stirrer. Aliquots 
(4ml)  of release  medium were withdrawn at different time 
intervals and the sample was replaced with fresh PBS (pH 
7.4) to maintain constant volume. 1 ml of Acetonitrile was 
added to each aliquot to precipitate the lipids and dissolve the 
entrapped Doxorubicin hydrochloride and then the samples 
were  analyzed  by  UV  spectrophotometry  at  a  λ  max  of 
254nm
9, 10, 11. 
 
Stability Studies 
The  stability  of  a  pharmaceutical  delivery  system  may  be 
defined  as  the  capability  of  a  particular  formulation,  in  a 
specific container. The short-term stability was conducted to 
monitor physical and chemical stabilities of the liquid form of 
doxorubicin  hydrochloride  liposomal  formulations  at  40
oc 
and room temperature for up to three months. The stability 
parameter, such as Assay was determined as function of the 
storage time. 
 
TABLE 1: FORMULATION VARIABLES OF DOXORUBICIN LIPOSOME INJECTION 
 
S. No  Formulation code  Ratios of W1:O:W1  % Drug loading  % Drug release after 7 days 
1  F1  1 : 1 : 2  83.54  85.43 
2  F2  1 : 2 : 2  79.43  65.27 
3  F3  1 : 2 : 4  92.63  84.13 
4  F4  1 : 2 : 6  80.43  68.76 
5  F5  1 : 4 : 4  79.64  54.53 
6  F6  1 : 4 : 6  75.66  49.64 
 
TABLE 2A: PROCESS VARIABLES OF DOXORUBICIN LIPOSOME INJECTION 
 
Optimized  
Formulation  (F3) 
Primary homogenization 
speed (rpm) 
Secondary homogenization 
speed (rpm) 
Particle Size (µm)  Entrapment Efficiency 
(%) 
F3A  12,000  5000  17  72.83 
F3B  10,000  5000  34  92.52 
F3C  8,000  5000  40  90.64 
F3D  10,000  4,000  52  84.32 
F3E  10,000  3,000  64  81.56 
F3F  10,000  12,000  9  68.65 
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TABLE 2B: PROCESS VARIABLES OF DOXORUBICIN LIPOSOME INJECTION 
 
Ideal Formulation  (F3)  Primary Time (min)  Secondary Time (min)  % Entrapment Efficiency 
F3B1  5  1  91.42 
F3B2  8  1  86.45 
F3B3  1  1  36.62 
F3B4  5  4  85.64 
F3B5  5  1  92.38 
F3B6  5  6  40.83 
 
TABLE 3:  STABILITY DATA AT 25°C 
 
Test  Initial  1 month  2 months  3 months 
Description  Red colour suspension  Red colour suspension  Red colour suspension  Red colour suspension 
% Free drug  8.62%  8.87%  8.98%  9.21% 
Assay  101.0%  100.7%  99.7%  99.1% 
 
 
 
 
Figure 1: FTIR of Doxorubicin hydrochloride 
 
 
 
Figure 2: FTIR of doxorubicin hydrochloride, DOPC, DPPG, cholesterol, triolein 
 
 
 
Figure 3:  Particle Size distribution for F3B5 formulation 
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Figure 4:  Zeta Potential for F3B5 formulation 
 
 
 
Figure 5: In-vitro release profile for F3B5 formulation 
 
RESULTS AND DISCUSSIONS 
Compatibility studies 
The  compatibility  between  the  drug,  lipids  and  other 
excipients was evaluated using FTIR peak matching method. 
There was no appearance or disappearance of  peaks in the 
drug-lipid  mixture,  which  confirmed  the  absence  of  any 
chemical  interaction  between  the  drug,  lipid  and  other 
chemicals as shown in Figure 1 & 2.  
 
Optimization  of  process  and  formulation  variables  for 
Doxorubicin liposomal  
The  Doxorubicin  Liposomes  were  prepared  by  Double 
Emulsion  technique  and  optimized  the  process-formulation 
variables such as ratio of inner aqueous phase (w1) to organic 
phase (o) to outer aqueous  phase (w2) and homogenization 
speeds (primary and secondary) which was given in the Table 
1 & 2. Out of six formulation variables, F3 was given highest 
% drug loading and more than 80% of drug was released after 
7  days.  Formulation  F3  was  selected  as  optimized 
compositions  for  further  process  variables  parameters  like 
primary and secondary homogenization speed shown in table 
2 and primary and secondary homogenization time shown in 
table 3. There was a significant difference in particle size and 
entrapment  efficiency  on  primary  and  secondary 
homogenization speed. Formulation F3B was selected as an 
optimized formulation as it was given maximum entrapment 
efficiency with desired particle size for further optimization 
parameters. There was a significant difference in particle size 
on primary homogenization time but no effect was observed 
of  secondary  homogenization  time  on  particle  size. 
Formulation F3B5 was chosen for further characterization of 
doxorubicin liposomes 
12,13,14,15 
 
Percent free drug 
The  percent  free  drug  was  determined  for  optimized 
formulation F3B5. The percent free drug for F3B5 formulation 
was obtained 8.62%. 
 
Doxorubicin HCl Assay 
The  Assay  was  determined  for  the  optimized  formulation 
F3B5.  The  assay  for  F3B5  formulation  was  achieved  101% 
which contained 8.62% of free drug and 92.38% of entrapped 
drug. 
 
Particle size analysis and Zeta potential 
The  particle  size  distribution  was  analyzed  for  optimized 
formulation  F3B5  of  Doxorubicin  HCl  Liposomes  by  wet 
method.  The  particle  size  and  Zeta  Potential  for  F3B5  was 
33.39μm (Figure 3) & -18.9mV (Figure 4) respectively. 
 
Scanning Electron Microscopy (SEM) 
The Morphology and surface appearance of Liposomes were 
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formulation showed that the liposomes have spherical shape 
having 33 ± 5 µm particle sizes. 
 
In vitro Release studies 
The in vitro dissolution profile for F3B5 formulations (Figure: 
6)  was  carried  out  by  membrane  diffusion  method.  The 
dissolution was carried out for a period of 7 days in saline 
phosphate  buffer  pH  7.4.  Initial  burst  release  (1day)  of 
liposomes was 26% and more than 90% of drug was release 
within 7 days.  
 
Stability Studies 
The stability of the Doxorubicin liposomes was evaluated for 
optimized  formulation  of  F3B5  after  storage  at  accelerated 
condition  at  25±2°C/60±5%  RH  for  3  months.  The 
Description,  %  free  drug  &  assays  of  the  samples  were 
determined as a function of the storage time. The Liposomes 
stored  at  25°C  were  found  to  be  stable  for  duration  of  3 
months. The results were showed in Table 3. 
 
CONCLUSION 
In  the  present  study,  attempts  were  made  to  prepare 
Doxorubicin HCl Liposomes for controlled release by double 
emulsion  solvent  evaporation  technique.  The  selection  of 
different  ratios  of  Inner  aqueous  phase:  Oil  phase:  Outer 
aqueous phase, speed of primary homogenization and time of 
primary and secondary homogenization were found to have 
played a predominant role in the preparation. The prepared 
liposomes were evaluated for % free drug, % assay, particle 
size, and zeta potential. More than 90% drug was entrapped 
with  double  emulsion  method.  The  optimized  formulation 
was exhibited more than 90% release of drug for a period of 
7 days. From the experimental results it was evidenced that 
the  controlled  release  of  Doxorubicin  liposomes  was 
successfully formulated with less side effects. 
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